Screener
Tyra Biosciences, Inc. TYRA Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Tyra Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220645
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $412,040 | $282,609 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $3,642 | $1,178 |
| Lease liabilities, current | 488 | 472 |
| Accrued expenses and other current liabilities | 15,126 | 16,444 |
| Total current liabilities | 19,256 | 18,094 |
| Lease liabilities, noncurrent | 5,209 | 5,338 |
Item 1. Condensed Financial Statements
FAQ
- What is Tyra Biosciences, Inc.'s accounts payable?
- Tyra Biosciences, Inc. (TYRA) reported accounts payable of $3.64M in Q1 2026.
- How has Tyra Biosciences, Inc.'s accounts payable changed year-over-year?
- Tyra Biosciences, Inc.'s accounts payable increased by 45.7% year-over-year, from $2.5M to $3.64M.
- What is the long-term trend for Tyra Biosciences, Inc.'s accounts payable?
- Over 5 years (2020 to 2025), Tyra Biosciences, Inc.'s accounts payable has grown at a 12.1% compound annual growth rate (CAGR), from $664K to $1.18M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Tyra Biosciences, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude